Skip to main content
SpringerLink
Log in

Rischio oncogeno da terapia sostitutiva in menopausa

  • Published:
L’Endocrinologo Aims and scope

Riassunto

Il rischio di tumore della mammella aumenta moderatamente nelle utilizzatrici di estrogeni e ancora più nelle utilizzatrici di estroprogestinici; tuttavia, l’aumento di rischio tende a scomparire dopo l’interruzione. Il rischio di tumore dell’endometrio è aumentato dalla somministrazione di estrogeni, ma tale aumento è quasi completamente eliminato dalla contemporanea somministrazione di progestinici. La terapia ormonale sostitutiva può aumentare anche il rischio di tumori dell’ovaio, mentre può avere un effetto protettivo sul tumore del colon.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Clinical Synthesis Panel on HRT. Hormone replacement therapy. Lancet 354: 152, 1999.

    Article  Google Scholar 

  2. Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE. Post-menopausal hormone therapy and mortality. N Engl J Med 336: 1769, 1997.

    Article  CAS  PubMed  Google Scholar 

  3. Beral V, Banks E, Reeves G, Appleby P. Use of HRT and the subsequent risk of cancer. J Epidemiol Biostatistics 4: 191, 1999.

    CAS  Google Scholar 

  4. IARC, International Agency for Research on Cancer. IARC monograph on the evaluation of carcinogenic risks to humans, Vol. 72. Hormonal contraception and post-menopausal hormonal therapy. IARC, Lyon, 1999.

    Google Scholar 

  5. Tavani A, La Vecchia C. The adverse effects of hormone replacement therapy. Drugs Aging 14: 347, 1999.

    Article  CAS  PubMed  Google Scholar 

  6. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 350: 1047, 1997.

    Article  Google Scholar 

  7. Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 15: 66, 1993.

    CAS  PubMed  Google Scholar 

  8. Willis DB, Calle EE, Miracle-McMahill FIL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of post-menopausal women in the United States. Cancer Causes Control 7: 449, 1996.

    Article  CAS  PubMed  Google Scholar 

  9. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of post-menopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 196: 433, 1995.

    CAS  PubMed  Google Scholar 

  10. The Writing Group on the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in post-menopausal women. The Postmenopausal Estrogen/Progestin Intervention (PEPI) Trial. JAMA 275: 370, 1996.

    Article  Google Scholar 

  11. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15: 17, 1993.

    CAS  PubMed  Google Scholar 

  12. Stanford JL, Thomas DH. Exogenous progestins and breast cancer. Epidemiol Rev 15: 98, 1993.

    CAS  PubMed  Google Scholar 

  13. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-proge-stin replacement. N Engl J Med 321: 293, 1989.

    Article  CAS  PubMed  Google Scholar 

  14. Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynaecol 94: 620, 1987.

    Article  CAS  PubMed  Google Scholar 

  15. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42: 832, 1988.

    Article  CAS  PubMed  Google Scholar 

  16. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy- long-term follow-up of a Swedish cohort. Int J Cancer 67: 327, 1996.

    Article  CAS  PubMed  Google Scholar 

  17. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N Engl J Med 332: 1589, 1995.

    Article  CAS  PubMed  Google Scholar 

  18. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin-replacement therapy and breast cancer risk. JAMA 283: 485, 2000.

    Article  CAS  PubMed  Google Scholar 

  19. Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ, Thun MI. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 153: 145, 2001.

    Article  CAS  PubMed  Google Scholar 

  20. Magnusson C, Baron JA, Correia N, Bergstrom R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81: 339, 1999.

    Article  CAS  PubMed  Google Scholar 

  21. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risks: estrogen versus estrogen plus progestin. J Natl Cancer Inst 92: 328, 2000.

    Article  CAS  PubMed  Google Scholar 

  22. Li CI, Weiss NS, Stanford JL, Daling JR. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 88: 2570, 2000.

    Article  CAS  PubMed  Google Scholar 

  23. La Vecchia C, Negri E, Franceschi S, Favero A, Nanni O, Filiberti R, Conti E, Montella M, Veronesi A, Ferraroni M. et al. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 72: 244, 1995.

    Article  PubMed Central  PubMed  Google Scholar 

  24. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265: 1985, 1991.

    Article  CAS  PubMed  Google Scholar 

  25. Greendale GA, Reboussin BA, Sie A, Singh HR, Olson LK, Gatewood O, Bassett LW, Wasilauskas C, Bush T, Barrett-Connor E. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Ann Intern Med 130: 262, 1999.

    Article  CAS  PubMed  Google Scholar 

  26. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151: 75, 1991.

    Article  CAS  PubMed  Google Scholar 

  27. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynaecol 97: 1080, 1990.

    Article  CAS  PubMed  Google Scholar 

  28. Schairer C, Gail M, Byme C, Rosenberg PS, Sturgeon SR, Brinton LA, Hoover RN. Estrogen replacement therapy and breast cancer survival in a large screening study. J Natl Cancer Inst 91: 264, 1999.

    Article  CAS  PubMed  Google Scholar 

  29. Ewertz M, Gillanders S, Meyer L, Zedeler K. Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 49: 526, 1991.

    Article  CAS  PubMed  Google Scholar 

  30. Gapstur SM, Morrow M, Sellers TA. Hormone replacement therapy and risk of breast cancer with favorable histology: results of the lowa Women’s Health Study. JAMA 281: 2091, 1999.

    Article  CAS  PubMed  Google Scholar 

  31. Chlebowski RT, McTiernan A. Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. J Clin Oncol 17: 130, 1999.

    CAS  PubMed  Google Scholar 

  32. Eden JA, Brush T, Nand S, Wren BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer. Menopause: J North Am Menopause Soc 2: 67, 1995.

    Article  Google Scholar 

  33. La Vecchia C, Brinton L, McTiernan A. Cancer risk associated with menopausal hormones. In: Menopause and Women’s Health: a Comprehensive Approach. GPO, Bethesda, 2001, in stampa.

    Google Scholar 

  34. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85: 304, 1995.

    Article  CAS  PubMed  Google Scholar 

  35. Day NE. Epidemiology: the role of multi-stage models. Cancer Surv 2: 579, 1983.

    Google Scholar 

  36. Finkle WD, Greenland S, Miettinen OS, Ziel HK. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control 6: 99, 1995.

    Article  CAS  PubMed  Google Scholar 

  37. Shields TS, Weiss NS, Voigt LF, Beresford SA. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. Epidemiology 10: 733, 1999.

    Article  CAS  PubMed  Google Scholar 

  38. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol 162: 502, 1990.

    Article  CAS  PubMed  Google Scholar 

  39. Brinton LA, Hoover RN, for the Endometrial Cancer Collaborative Group. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 81: 265, 1993.

    CAS  PubMed  Google Scholar 

  40. Levi F, La Vecchia C, Gulie C, Franceschi S, Negri E. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 29A: 1445, 1993.

    Article  CAS  PubMed  Google Scholar 

  41. Weiderpass E, Adami HO, Baron JA, Magnusson C, Bergstrom R, Lindgren A, Correia N, Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91: 1131–1999.

  42. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338: 274, 1991.

    Article  CAS  PubMed  Google Scholar 

  43. Beresford SAA, Weiss NS, Voigt LF, McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349: 458, 1997.

    Article  CAS  PubMed  Google Scholar 

  44. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, Mack TM. Estrogen-progestin replacement therapy and endometrial cancer. J NatI Cancer Inst 89: 1110, 1997.

    Article  CAS  Google Scholar 

  45. Persson I, Thurfjell E, Bergstrom R, Holmberg L. Hormone replacement therapy and the risk of breast cancer Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer 72: 758, 1997.

    Article  CAS  PubMed  Google Scholar 

  46. Jain MG, Rhoan TE, Howe GR. Hormonal replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 53: 385, 2000.

    Article  CAS  PubMed  Google Scholar 

  47. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994–1997. Cancer Cases Control 12: 111, 2001.

    Article  CAS  Google Scholar 

  48. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 70: 289, 1987.

    CAS  PubMed  Google Scholar 

  49. Schairer C, Adami HO, Hoover R, Persson I. Causes-specific mortality in women receiving hormone replacement therapy. Epidemiology 8: 59, 1997.

    Article  CAS  PubMed  Google Scholar 

  50. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 141: 828, 1995.

    CAS  PubMed  Google Scholar 

  51. Rodriguez C, Patel AV, Calle EE, Jacob EJ, Thun MJ. Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. JAMA 285: 1460, 2001.

    Article  CAS  PubMed  Google Scholar 

  52. Whittemore AS, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies II. Invasive epithelial ovarian cancers in White women. Am J Epidemiol 136: 1184, 1992.

    CAS  PubMed  Google Scholar 

  53. Negri E, Tzonou A, Beral V, Lagiou P, Trichopoulos D, Parazzini F, Franceschi S, Booth M, La Vecchia C. Hormonal therapy for menopause and ovarian cancer in a collaborative re-analysis of European studies. Int J Cancer 80: 848, 1999.

    Article  CAS  PubMed  Google Scholar 

  54. Garg PP, Kerlikowske K, Subak L, Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: A meta-analysis. Obstet Gynecol 92: 472, 1998.

    Article  CAS  PubMed  Google Scholar 

  55. La Vecchia C, Negri E, Levi F, Decarli A, Boyle P. Cancer mortality in Europe: effects of age, cohort of birth and period of death. Eur J Cancer 34: 118, 1998.

    Article  PubMed  Google Scholar 

  56. Franceschi S, La Vecchia C. Colorectal cancer and hormone replacement therapy: an unexpected finding. Eur J Cancer 7: 427, 1998.

    Article  CAS  Google Scholar 

  57. La Vecchia C, Brinton LA, McTiernan A. Menopause, hormone replacement therapy and cancer. Maturitas 25: 97, 2001.

    Article  Google Scholar 

  58. Calle EE, Miracle-McMahilI HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and risk of fatal colon cancer in a prospective cohort of post-menopausal women. J Natl Cancer Inst 87: 517, 1995.

    Article  CAS  PubMed  Google Scholar 

  59. Paganini-Hill A. Estrogen replacement therapy and colorectal cancer risk in elderly women. Dis Colon Rectum 42: 1300, 1999.

    Article  CAS  PubMed  Google Scholar 

  60. Femandez E, Franceschi S, La Vecchia C. Colorectal cancer and hormone replaement therapy: A review of epidemiological studies. J Br Menop Soc 6: 8, 2000.

    Article  Google Scholar 

  61. Herbert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer among women. Cancer Epidemiol Biomarkers Prev 7: 653, 1998.

    Google Scholar 

  62. Barrett-Connor E. Postmenopausal estrogen and prevention bias. Ann Intem Med 115: 455, 1991.

    Article  CAS  Google Scholar 

  63. Slattery ML, Anderson K, Samowitz W, Edwards SL, Curtin K, Caan B, Potter JD. Hormone replacement therapy and improved survival among post-menopausal women diagnosed with colon cancer (USA). Cancer Causes Control 10: 467, 1999.

    Article  CAS  PubMed  Google Scholar 

  64. McMichael AJ, Potter JD. Host factors in carcinogenesis: certain bile-acid metabolic profiles that selectively increase the risk of proximal colon cancer. J Natl Cancer Inst 75: 185, 1985.

    CAS  PubMed  Google Scholar 

  65. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7: 536, 1994.

    Article  CAS  PubMed  Google Scholar 

  66. Fernandez E, La Vecchia C, Balducci A, Chatenoud L, Franceschi S, Negri E. Oral contraceptives and colorectal cancer risk: A meta-analysis. Br J Cancer 84: 722, 2001.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  67. Fisher B, Constantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Tobioux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolinark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371–1388, 1998.

    Article  CAS  PubMed  Google Scholar 

  68. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Daley J. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemo-prevention trial. Lancet 352: 98–101, 1998.

    Article  CAS  PubMed  Google Scholar 

  69. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P. Prevention of breast cancer with tarnoxifen: preliminary fmdings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352: 93, 1998.

    Article  CAS  PubMed  Google Scholar 

  70. Gail MH, Constantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829, 1999.

    Article  CAS  PubMed  Google Scholar 

  71. Cummings SB, Eckert S, Kreuger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. The effects of raloxifene on risk of breast cancer in post-menopausal women. Results from the MORE randomized trial. JAMA 281: 2189, 1999.

    Article  CAS  PubMed  Google Scholar 

  72. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 321: 293, 1989.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Ricerche Farmacologiche “Mario Negri”, Via Eritrea, 62, 20157, Milano, Italia

    Carlo La Vecchia, Andrea Altieri & Alessandra Tavani

  2. Istituto di Statistica Medica e Biometria, Università degli Studi di Milano, Milano, Italia

    Carlo La Vecchia

Authors
  1. Carlo La Vecchia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Altieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandra Tavani
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carlo La Vecchia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

La Vecchia, C., Altieri, A. & Tavani, A. Rischio oncogeno da terapia sostitutiva in menopausa. L’Endocrinologo 2, 140–147 (2001). https://doi.org/10.1007/BF03344399

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344399

Search

Navigation